Pathological	0	12	O
animal	13	19	O
models	20	26	O
in	27	29	O
the	30	33	O
experimental	34	46	O
evaluation	47	57	O
of	58	60	O
tumour	61	67	B-Tissue
microvasculature	68	84	I-Tissue
with	85	89	O
magnetic	90	98	O
resonance	99	108	O
imaging	109	116	O
.	116	117	O

PURPOSE	119	126	O
:	126	127	O
The	128	131	O
purpose	132	139	O
of	140	142	O
this	143	147	O
study	148	153	O
was	154	157	O
to	158	160	O
evaluate	161	169	O
the	170	173	O
applications	174	186	O
of	187	189	O
magnetic	190	198	O
resonance	199	208	O
imaging	209	216	O
(	217	218	O
MRI	218	221	O
)	221	222	O
,	222	223	O
and	224	227	O
in	228	230	O
particular	231	241	O
,	241	242	O
dynamic	243	250	O
contrast	251	259	O
-	259	260	O
enhanced	260	268	O
MRI	269	272	O
(	273	274	O
DCE	274	277	O
-	277	278	O
MRI	278	281	O
)	281	282	O
,	282	283	O
in	284	286	O
the	287	290	O
assessment	291	301	O
of	302	304	O
tumour	305	311	B-Tissue
microvasculature	312	328	I-Tissue
by	329	331	O
means	332	337	O
of	338	340	O
animal	341	347	O
tumour	348	354	B-Pathological_formation
models	355	361	O
evaluated	362	371	O
before	372	378	O
and	379	382	O
after	383	388	O
antiangiogenic	389	403	O
treatment	404	413	O
.	413	414	O

MATERIALS	415	424	O
AND	425	428	O
METHODS	429	436	O
:	436	437	O
Forty	438	443	O
-	443	444	O
two	444	447	O
MRI	448	451	O
exams	452	457	O
were	458	462	O
performed	463	472	O
with	473	477	O
intravascular	478	491	O
contrast	492	500	O
media	501	506	O
in	507	509	O
21	510	512	O
rats	513	517	B-Organism
:	517	518	O
tumours	519	526	B-Pathological_formation
were	527	531	O
induced	532	539	O
by	540	542	O
subcutaneous	543	555	O
injection	556	565	O
of	566	568	O
colon	569	574	B-Cell
carcinoma	575	584	I-Cell
cells	585	590	I-Cell
in	591	593	O
7	594	595	O
rats	596	600	B-Organism
and	601	604	O
mammary	605	612	B-Cell
adenocarcinoma	613	627	I-Cell
cells	628	633	I-Cell
in	634	636	O
14	637	639	O
rats	640	644	B-Organism
.	644	645	O

Perfusion	646	655	O
and	656	659	O
permeability	660	672	O
parameters	673	683	O
of	684	686	O
the	687	690	O
implanted	691	700	O
tumours	701	708	B-Pathological_formation
were	709	713	O
evaluated	714	723	O
by	724	726	O
using	727	732	O
two	733	736	O
contrast	737	745	O
media	746	751	O
(	752	753	O
B22956	753	759	B-Drug_or_compound
/	759	760	I-Drug_or_compound
1	760	761	I-Drug_or_compound
and	762	765	O
Gd	766	768	B-Drug_or_compound
-	768	769	I-Drug_or_compound
DTPA37	769	775	I-Drug_or_compound
-	775	776	I-Drug_or_compound
albumin	776	783	I-Drug_or_compound
)	783	784	O
to	785	787	O
establish	788	797	O
response	798	806	O
to	807	809	O
treatment	810	819	O
with	820	824	O
two	825	828	O
different	829	838	O
antiangiogenic	839	853	O
drugs	854	859	O
(	860	861	O
tamoxifen	861	870	B-Drug_or_compound
and	871	874	O
SU6668	875	881	B-Drug_or_compound
)	881	882	O
.	882	883	O

These	884	889	O
parameters	890	900	O
were	901	905	O
correlated	906	916	O
with	917	921	O
histology	922	931	O
to	932	934	O
obtain	935	941	O
a	942	943	O
radiological	944	956	O
-	956	957	O
histological	957	969	O
map	970	973	O
of	974	976	O
tumour	977	983	B-Tissue
microvasculature	984	1000	I-Tissue
.	1000	1001	O

RESULTS	1002	1009	O
:	1009	1010	O
DCE	1011	1014	O
-	1014	1015	O
MRI	1015	1018	O
revealed	1019	1027	O
greater	1028	1035	O
enhancement	1036	1047	O
in	1048	1050	O
the	1051	1054	O
peripheral	1055	1065	O
area	1066	1070	O
than	1071	1075	O
in	1076	1078	O
the	1079	1082	O
central	1083	1090	O
area	1091	1095	O
in	1096	1098	O
all	1099	1102	O
the	1103	1106	O
examined	1107	1115	O
animal	1116	1122	O
models	1123	1129	O
.	1129	1130	O

In	1131	1133	O
the	1134	1137	O
mammary	1138	1145	B-Pathological_formation
carcinoma	1146	1155	I-Pathological_formation
experiment	1156	1166	O
,	1166	1167	O
vascular	1168	1176	B-Multi-tissue_structure
permeability	1177	1189	O
measured	1190	1198	O
by	1199	1201	O
means	1202	1207	O
of	1208	1210	O
B22956	1211	1217	B-Drug_or_compound
/	1217	1218	I-Drug_or_compound
1	1218	1219	I-Drug_or_compound
in	1220	1222	O
the	1223	1226	O
animals	1227	1234	O
treated	1235	1242	O
with	1243	1247	O
the	1248	1251	O
antiangiogenic	1252	1266	O
drug	1267	1271	O
(	1272	1273	O
0	1273	1274	O
.	1274	1275	O
0043317	1275	1282	O
+	1282	1283	O
/	1283	1284	O
-	1284	1285	O
0	1285	1286	O
.	1286	1287	O
0040418	1287	1294	O
ml	1295	1297	O
/	1297	1298	O
min	1298	1301	O
(	1301	1302	O
-	1302	1303	O
1	1303	1304	O
)	1304	1305	O
/	1305	1306	O
ml	1306	1308	O
(	1308	1309	O
-	1309	1310	O
1	1310	1311	O
)	1311	1312	O
)	1312	1313	O
was	1314	1317	O
significantly	1318	1331	O
less	1332	1336	O
than	1337	1341	O
in	1342	1344	O
untreated	1345	1354	O
animals	1355	1362	O
(	1363	1364	O
0	1364	1365	O
.	1365	1366	O
0090460	1366	1373	O
+	1373	1374	O
/	1374	1375	O
-	1375	1376	O
0	1376	1377	O
.	1377	1378	O
0043680	1378	1385	O
ml	1386	1388	O
/	1388	1389	O
min	1389	1392	O
(	1392	1393	O
-	1393	1394	O
1	1394	1395	O
)	1395	1396	O
/	1396	1397	O
ml	1397	1399	O
(	1399	1400	O
-	1400	1401	O
1	1401	1402	O
)	1402	1403	O
)	1403	1404	O
,	1404	1405	O
whereas	1406	1413	O
no	1414	1416	O
significant	1417	1428	O
difference	1429	1439	O
was	1440	1443	O
observed	1444	1452	O
with	1453	1457	O
Gd	1458	1460	B-Drug_or_compound
-	1460	1461	I-Drug_or_compound
DTPA	1461	1465	I-Drug_or_compound
-	1465	1466	I-Drug_or_compound
albumin	1466	1473	I-Drug_or_compound
(	1474	1475	O
13	1475	1477	O
.	1477	1478	O
14	1478	1480	O
+	1480	1481	O
/	1481	1482	O
-	1482	1483	O
13	1483	1485	O
.	1485	1486	O
94	1486	1488	O
ml	1489	1491	O
/	1491	1492	O
min	1492	1495	O
(	1495	1496	O
-	1496	1497	O
1	1497	1498	O
)	1498	1499	O
/	1499	1500	O
ml	1500	1502	O
(	1502	1503	O
-	1503	1504	O
1	1504	1505	O
)	1505	1506	O
in	1507	1509	O
treated	1510	1517	O
animals	1518	1525	O
and	1526	1529	O
18	1530	1532	O
.	1532	1533	O
07	1533	1535	O
+	1535	1536	O
/	1536	1537	O
-	1537	1538	O
11	1538	1540	O
.	1540	1541	O
92	1541	1543	O
ml	1544	1546	O
/	1546	1547	O
min	1547	1550	O
(	1550	1551	O
-	1551	1552	O
1	1552	1553	O
)	1553	1554	O
/	1554	1555	O
ml	1555	1557	O
(	1557	1558	O
-	1558	1559	O
1	1559	1560	O
)	1560	1561	O
in	1562	1564	O
untreated	1565	1574	O
animals	1575	1582	O
)	1582	1583	O
.	1583	1584	O

In	1585	1587	O
the	1588	1591	O
colon	1592	1597	B-Pathological_formation
carcinoma	1598	1607	I-Pathological_formation
experiment	1608	1618	O
,	1618	1619	O
mean	1620	1624	O
permeability	1625	1637	O
and	1638	1641	O
perfusion	1642	1651	O
decreased	1652	1661	O
by	1662	1664	O
51	1665	1667	O
%	1667	1668	O
(	1669	1670	O
from	1670	1674	O
5	1675	1676	O
.	1676	1677	O
2	1677	1678	O
+	1678	1679	O
/	1679	1680	O
-	1680	1681	O
1	1681	1682	O
.	1682	1683	O
1	1683	1684	O
to	1685	1687	O
2	1688	1689	O
.	1689	1690	O
5	1690	1691	O
+	1691	1692	O
/	1692	1693	O
-	1693	1694	O
0	1694	1695	O
.	1695	1696	O
8	1696	1697	O
ml	1698	1700	O
/	1700	1701	O
100	1701	1704	O
ml	1705	1707	O
)	1707	1708	O
and	1709	1712	O
59	1713	1715	O
%	1715	1716	O
(	1717	1718	O
from	1718	1722	O
0	1723	1724	O
.	1724	1725	O
00165	1725	1730	O
+	1730	1731	O
/	1731	1732	O
-	1732	1733	O
5	1733	1734	O
.	1734	1735	O
1	1735	1736	O
to	1737	1739	O
0	1740	1741	O
.	1741	1742	O
0067	1742	1746	O
+	1746	1747	O
/	1747	1748	O
-	1748	1749	O
4	1749	1750	O
.	1750	1751	O
8	1751	1752	O
ml	1753	1755	O
/	1755	1756	O
min	1756	1759	O
(	1759	1760	O
-	1760	1761	O
1	1761	1762	O
)	1762	1763	O
/	1763	1764	O
ml	1764	1766	O
(	1766	1767	O
-	1767	1768	O
1	1768	1769	O
)	1769	1770	O
of	1771	1773	O
tissue	1774	1780	B-Tissue
)	1780	1781	O
,	1781	1782	O
respectively	1783	1795	O
,	1795	1796	O
in	1797	1799	O
all	1800	1803	O
animals	1804	1811	O
after	1812	1817	O
antiangiogenic	1818	1832	O
drug	1833	1837	O
administration	1838	1852	O
.	1852	1853	O

CONCLUSIONS	1854	1865	O
:	1865	1866	O
DCE	1867	1870	O
-	1870	1871	O
MRI	1871	1874	O
permits	1875	1882	O
a	1883	1884	O
noninvasive	1885	1896	O
evaluation	1897	1907	O
of	1908	1910	O
tumour	1911	1917	B-Pathological_formation
microcirculation	1918	1934	O
and	1935	1938	O
in	1939	1941	O
particular	1942	1952	O
of	1953	1955	O
its	1956	1959	O
dynamic	1960	1967	O
characteristics	1968	1983	O
and	1984	1987	O
vascularity	1988	1999	O
before	2000	2006	O
and	2007	2010	O
after	2011	2016	O
antiangiogenic	2017	2031	O
treatment	2032	2041	O
.	2041	2042	O

